ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • Technology
  • Publications

Publications

Publications and Conference Presentations
IMC-001
Category Title Conference·
Journal Name		 Date of
Presentation
Conference Neoadjuvant Anti-PD-L1 Antibody Therapy with Daburstotug (IMC-001) in Resectable Gastric, Esophageal, and Hepatocellular Carcinoma; A Multicohort Phase Ⅱ Trial (NeoChance Study) 2025 ESMO(European Society of Medical Oncology) 2025-10-19
Conference Exploring Exposure-response(E-R) relationship of PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell Lymphoma nasal type(ENKTL) patients 2024 ACoP(American Conference on Pharmacometrics) 2024-11-13
Conference Optimizing IMC-001 Dosage Regimens Using Target Mediated Drug Disposition Model: Enhancing Therapeutic Efficacy and Safety in Cancer Treatment 2024 PAGE(Population Approach Group Europe) 2024-06-26
Conference Enhanced Efficacy and Safety from Phase 2 Study of IMC-001, an Anti-PD-L1 Antibody, in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma (R/R ENKTL), Nasal Type: DISTINKT Study 2024 EHA(European Hematology Association) 2024-06-13
Conference Phase 2 study to investigate the efficacy and safety of IMC-001, anti-PD-L1 antibody, in patients with relapsed or refractory extranodal NK/T cell Lymphoma, nasal type: DISTINKT Study 2023 ICML(International Conference on Malignant Lymphoma) 2023-06-13
Conference A Phase Ⅱ study of neoadjuvant immune checkpoint inhibitor IMC-001 (anti-PD-L1 antibody) in patients with resectable upper gastrointestinal cancers (Neo-Chance Study) 2023 AACR(American Association for Cancer Research) 2023-04-14
Conference A Phase 1 Study of IMC-001, a PD-L1 Blocker, in Patients with Metastatic or Locally Advanced Solid Tumors 2020 SITC(Society for Immunotherapy of Cancer) 2020-11-09
IMC-002
Category Title Conference·
Journal Name		 Date of
Presentation
Conference Enhanced Safety Profile of IMC-002, and Affinity-Optimized Anti-CD47 Antibody: Preclinical and Phase 1a/1b Findings 2025 ESMO(European Society of Medical Oncology) 2025-10-19
Conference Phase 1b Dose Extension Study of a Next-Generation Anti-CD47 Monoclonal Antibody IMC-002 Combined with Lenvatinib in Patients with Advanced Hepatocellular Carcinoma(HCC) 2025 ASCO(American Society of Clinical Oncology) 2025-09-11
Conference Development of IMC-002, a next-generation anti-CD47 mAb: An affinity optimized antibody with enhanced safety and therapeutic efficacy in preclinical models. 2025 AACR(American Association for Cancer Research) 2025-04-25
Conference Updated Safety, Efficacy, Pharmacokinetics, and Biomarkers from The Phase 1 Study of IMC-002, a Novel Anti-CD47 Monoclonal Antibody, in Patients with Advanced Solid Tumors. 2024 ASCO(American Society of Clinical Oncology) 2024-05-31
Conference Phase 1 dose escalation study of IMC-002, a novel anti-CD47 Monoclonal antibody, in patients with advanced solid tumors 2023 ESMO(European Society for Medical Oncology) 2023-10-20
IMC-201
Category Title Conference·
Journal Name		 Date of
Presentation
Conference IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumors 2022 AACR(American Association for Cancer Research) 2022-04-08